Review of the ASCO and IDSA clinical practice guidelines on antimicrobial prophylaxis for adult patients with cancer-related immunosupression

V. Veselov Alexander; N.P.  Shevchenko

doi:10.36488/cmac.2019.1.4-17

Review of the ASCO and IDSA clinical practice guidelines on antimicrobial prophylaxis for adult patients with cancer-related immunosupression

Clinical Microbiology and Antimicrobial Chemotherapy. 2019; 21(1):4-17

Veselov A.V., Shevchenko N.P.

10.36488/cmac.2019.1.4-17

prophylaxis neutropenia malignancy antimicrobials

Section

Clinical Guidelines

Type

Journal article

Publication

Clinical Microbiology and Antimicrobial Chemotherapy. 2019; 21(1):4-17

Abstract Authors Literature PDF Statistics

Abstract

Patients undergoing cytotoxic chemotherapy and hematopoietic stem-cell transplantation are at risk for infection. The risk of infections increases with the depth and duration of neutropenia, with the greatest risk occurring in patients who experience profound, prolonged neutropenia after chemotherapy, which is most likely to occur in the period before engraftment during hematopoietic stem-cell transplantation and after induction chemotherapy for acute leukemia, as well as in other situations that are accompanied by deep long-term neutropenia. Those patients represent a high-risk group for which antimicrobial prophylaxis is recommended. The updated version of the recommendations developed by the American Society of Clinical Oncology (ASCO) and the Infectious Diseases Society of America (IDSA) includes the information on antibacterial, antifungal, and antiviral prophylaxis in this patient population. The article includes a comparative analysis of some other published international guidelines on this topic, including the US National Comprehensive Cancer Network (NCCN) for the Prevention and Treatment of Cancer-Related Infections and the European Conference on Infections in Patients with Leukemia (ECIL) for primary antifungal prophylaxis in adult patients with hematological malignancies.

Alexander V. Veselov

Alex.Veselov@antibiotic.ru

0000-0003-4683-1566

Institute of Antimicrobial Chemotherapy, Smolensk State Medical University, Smolensk, Russia

Shevchenko N.P.

Clinical Oncology Dispensary #1, Kuban State Medical University, Krasnodar, Russia

1. Sievers E.L., Dale D.C., Bolyard A.A., et al. Types of severe chronic neutropenia. Available at: www.neutropenia.ca/about/types-of-neutropenia?phpMyAdmin=8c01cfac7abc247071277b7622ac9394.
2. Bow E., Wingard J.R. Overview of neutropenic fever syndromes. Available at: www.uptodate.com/contents/overview-of-neutropenicfever-syndromes.
3. Carmona-Bayonas A., Jimenez-Fonseca P., Virizuela Echaburu J., et al. Prediction of serious complications in patients with seemingly stable febrile neutropenia: Validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study. J Clin Oncol. 2015;33:465-471. DOI: 10.1200/JCO.2014.57.2347
4. Kuderer N.M., Dale D.C., Crawford J., et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106:2258-2266. DOI: 10.1002/cncr.21847
5. Legrand M., Max A., Peigne V., et al. Survival in neutropenic patients with severe sepsis or septic shock. Crit Care Med. 2012;40:43-49. DOI: 10.1097/CCM.0b013e31822b50c2
6. Flowers C.R., Seidenfeld J., Bow E.J., et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013;31:794-810. DOI: 10.1200/JCO.2012.45.8661
7. Freifeld A.G., Bow E.J., Sepkowitz K.A., et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:e56-e93. DOI: 10.1093/cid/cir073
8. Brozek J.L., Akl E.A., Compalati E., et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines part 3 of 3. The GRADE approach to developing recommendations. Allergy. 2011;66:588-595. DOI: 10.1111/j.1398-9995.2010.02530.x
9. Taplitz R.A., Kennedy E.B., Bow E.J., et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America clinical practice guideline update. J Clin Oncol. 2018;36:1443-1453. DOI: 10.1200/JCO.2017.77.6211
10. Tomblyn M., Chiller T., Einsele H., et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: A global perspective. Preface. Bone Marrow Transplant. 2009;44:453-455. DOI: 10.1038/bmt.2009.254
11. NCCN Clinical Practice Guidelines in Oncology. Prevention and Treatment of Cancer-Related Infections. Available at: www.nccn.org/professionals/physician_gls/default.aspx.
12. Maertens J.A., Girmenia C., Brüggemann R.J., et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother. 2018;73(12):3221-3230. DOI: 10.1093/jac/dky286
13. Agrawal S., Jones B., Barnes R., et al. A practical critique of antifungal treatment guidelines for haemato-oncologists. Crit Rev Microbiol. 2012;38:203-216. DOI: 10.3109/1040841X.2011.645521
14. Shiffman R.N., Michel G., Rosenfeld R.M., et al. Building better guidelines with BRIDGE-Wiz: Development and evaluation of a software assistant to promote clarity, transparency, and implementability. J Am Med Inform Assoc. 2012;19:94-101. DOI: 10.1136/amiajnl-2011-000172
15. Ullmann A.J., Lipton J.H., Vesole D.H., et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356:335-347. DOI: 10.1056/NEJMoa061098
16. Hwang J.P., Somerfield M.R., Alston-Johnson D.E., et al. Hepatitis B virus screening for patients with cancer before therapy: American Society of Clinical Oncology provisional clinical opinion update. J Clin Oncol. 2015;33:2212-2220. DOI: 10.1200/JCO.2015.61.3745
17. Rubin L.G., Levin M.J., Ljungman P., et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:e44-e100. DOI: 10.1093/cid/cit684
18. Lyman G.H., Abella E., Pettengell R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. Crit Rev Oncol Hematol. 2014;90:190-199. DOI: 10.1016/j.critrevonc.2013.12.006
19. Lyman G.H., Dale D.C., Friedberg J., et al. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma: A nationwide study. J Clin Oncol. 2004;22:4302-4311. DOI: 10.1200/JCO.2004.03.213
20. Intragumtornchai T., Sutheesophon J., Sutcharitchan P., et al. A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin’s lymphoma. Leuk Lymphoma. 2000;37:351-360. DOI: 10.3109/10428190009089435
21. Cullen M.H., Billingham L.J., Gaunt C.H., et al. Rational selection of patients for antibacterial prophylaxis after chemotherapy. J Clin Oncol. 2007;25:4821-4828. DOI: 10.1200/JCO.2006.08.7395
22. Hosmer W., Malin J., Wong M. Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer. Support Care Cancer. 2011;19:333341. DOI: 10.1007/s00520-010-0821-1
23. Bow E.J. Infectious complications in patients receiving cytotoxic therapy for acute leukemia: History, background, and approaches to management, in Wingard J.R., Bowden R.A. (eds.): Management of Infection in Oncology Patients. London, United Kingdom, Martin Dunitz, 2003, pp. 71-104. DOI: 10.1201/b14652
24. Gardner A., Mattiuzzi G., Faderl S., et al. Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia. J Clin Oncol. 2008;26:5684-5688. DOI: 10.1200/JCO.2008.16.4681
25. Klastersky J., Paesmans M., Rubenstein E.B., et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038-3051. DOI: 10.1200/JCO.2000.18.16.3038
26. Bow E.J., Meddings J.B. Intestinal mucosal dysfunction and infection during remission-induction therapy for acute myeloid leukaemia. Leukemia. 2006;20:2087-2092. DOI: 10.1038/sj.leu.2404440
27. Romaguera J.E., Fayad L., Rodriguez M.A., et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantlecell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005;23:7013-7023. DOI: 10.1200/JCO.2005.01.1825
28. Ray-Coquard I., Borg C., Bachelot T., et al. Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. Br J Cancer. 2003;88:181-186. DOI: 10.1038/sj.bjc.6600724
29. Pettengell R., Schwenkglenks M., Leonard R., et al. Neutropenia occurrence and predictors of reduced chemotherapy delivery: Results from the INC-EU prospective observational European neutropenia study. Support Care Cancer. 2008;16:1299-1309. DOI: 10.1007/s00520-008-0430-4
30. Talcott J.A., Finberg R., Mayer R.J., et al. The medical course of cancer patients with fever and neutropenia. Clinical identification of a lowrisk subgroup at presentation. Arch Intern Med. 1988;148:25612568. DOI: 10.1001/archinte.1988.00380120031007
31. Bow E.J., Kilpatrick M.G., Scott B.A., et al. Acute myeloid leukemia in Manitoba. The consequences of standard “7 + 3” remission-induction therapy followed by high dose cytarabine postremission consolidation for myelosuppression, infectious morbidity, and outcome. Cancer. 1994;74:52-60. DOI: 10.1002/1097-0142(19940701)74:1<52::AIDCNCR2820740110>3.0.CO;2-G
32. Talcott J.A., Siegel R.D., Finberg R., et al. Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule. J Clin Oncol. 1992;10:316-322. DOI: 10.1200/JCO.1992.10.2.316
33. Schwenkglenks M., Jackisch C., Constenla M., et al. Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment. Support Care Cancer. 2006;14:901-909. DOI: 10.1007/s00520-006-0034-9
34. Sonis S.T., Oster G., Fuchs H., et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol. 2001;19:2201-2205. DOI: 10.1200/JCO.2001.19.8.2201
35. Bodey G.P., Buckley M., Sathe Y.S., et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64:328-340. DOI: 10.7326/00034819-64-2-328
36. Blay J.Y., Chauvin F., Le Cesne A., et al. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol. 1996;14:636-643. DOI: 10.1200/JCO.1996.14.2.636
37. Bodey G.P., Rodriguez V., Chang H.Y., et al. Fever and infection in leukemic patients: A study of 494 consecutive patients. Cancer. 1978;41:16101622. DOI: 10.1002/1097-0142(197804)41:4<1610::AIDCNCR2820410452>3.0.CO;2-B
38. Hughes W.T., Armstrong D., Bodey G.P., et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730-751. DOI: 10.1086/339215
39. Oguz A., Karadeniz C., Ckitak E.C., et al. Which one is a risk factor for chemotherapy-induced febrile neutropenia in childhood solid tumors: Early lymphopenia or monocytopenia? Pediatr Hematol Oncol. 2006;23:143-151. DOI: 10.1080/08880010500457673
40. Aapro M.S., Cameron D.A., Pettengell R., et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 2006;42:2433-2453. DOI: 10.1016/j.ejca.2006.05.002
41. Heidenreich D., Kreil S., Nolte F., et al. Allogeneic hematopoietic cell transplantation without fluconazole and fluoroquinolone prophylaxis. Ann Hematol. 2016;95:287-293. DOI: 10.1007/s00277-0152535-4
42. Spellberg B., Doi Y. The rise of fluoroquinolone-resistant Escherichia coli in the community: Scarier than we thought. J Infect Dis. 2015;212:1853-1855. DOI: 10.1093/infdis/jiv279
43. Trecarichi E.M., Tumbarello M., Spanu T., et al. Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect. 2009;58:299-307. DOI: 10.1016/j.jinf.2009.02.002
44. Kuzmenkov A.Yu, Trushin I.V, Avramenko A.A., et al. AMRmap: an online platform for monitoring antibiotic resistance. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2017;19(2):84-90.
45. Bow E.J. Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients. Curr Opin Infect Dis. 2011;24:545-553. DOI: 10.1097/QCO.0b013e32834cf054
46. Gafter-Gvili A., Fraser A., Paul M., et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev. 2012;1:CD004386. DOI: 10.1002/14651858.CD004386.pub3
47. Bucaneve G., Micozzi A., Menichetti F., et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005;353:977-987. DOI: 10.1056/NEJMoa044097
48. US Food and Drug Administration: FDA updates warnings for fluoroquinolone antibiotics. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm513183.htm.
49. Wojenski D.J., Barreto J.N., Wolf R.C., et al. Cefpodoxime for antimicrobial prophylaxis in neutropenia: A retrospective case series. Clin Ther. 2014;36:976-981. DOI: 10.1016/j.clinthera.2014.04.013
50. Fietz T., Lück A., Schulz H., et al. Prophylaxis of chemotherapyinduced neutropenia and febrile neutropenia with lipegfilgrastim in 2489 cancer patients: final results from the non-interventional study NADIR. Curr Med Res Opin. 2018;(Dec 17):1-12. DOI: 10.1080/03007995.2018.1560200
51. Weycker D., Bensink M., Lonshteyn A., Doroff R., Chandler D. Use of colony-stimulating factor primary prophylaxis and incidence of febrile neutropenia from 2010-2016: a longitudinal assessment. Curr Med Res Opin. 2018;(Dec 14):1-15. DOI: 10.1080/03007995.2018.1558851
52. Carmona-Bayonas A., Jimenez-Fonseca P., de Castro E.M., et al. SEOM clinical practice guideline: management and prevention of febrile neutropenia in adults with solid tumors (2018). Clin Transl Oncol. 2019;21(1):75-86. DOI: 10.1007/s12094-018-1983-4
53. Kulkarni S., Powles R., Treleaven J., et al. Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants. Blood. 2000;95:36833686. www.bloodjournal.org/content/95/12/3683.
54. Engelhard D., Cordonnier C., Shaw P.J., et al. Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survey. Br J Haematol. 2002;117:444450. DOI: 10.1046/j.1365-2141.2002.03457.x
55. Youssef S., Rodriguez G., Rolston K.V., et al. Streptococcus pneumoniae infections in 47 hematopoietic stem cell transplantation recipients: clinical characteristics of infections and vaccine-breakthrough infections, 1989-2005. Medicine (Baltimore). 2007;86:69-77. DOI: 10.1097/md.0b013e31803eb176
56. Engelhard D., Akova M., Boeckh M.J., et al. Bacterial infection prevention after hematopoietic cell transplantation. Bone Marrow Transplant. 2009;44:467-470. DOI: 10.1038/bmt.2009.257
57. Blennow O., Remberger M., Klingspor L., et al. Randomized PCRbased therapy and risk factors for invasive fungal infection following reduced-intensity conditioning and hematopoietic SCT. Bone Marrow Transplant. 2010;45:1710-1718. DOI: 10.1038/bmt.2010.38
58. Klingspor L., Saaedi B., Ljungman P., et al. Epidemiology and outcomes of patients with invasive mould infections: A retrospective observational study from a single centre (2005-2009). Mycoses. 2015;58:470-477. DOI: 10.1111/myc.12344
59. Kontoyiannis D.P., Marr K.A., Park B.J., et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) database. Clin Infect Dis. 2010;50:1091-1100. DOI: 10.1086/651263
60. Sun Y., Meng F., Han M., et al. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: A multicenter prospective observational study. Biol Blood Marrow Transplant. 2015;21:1117-1126. DOI: 10.1016/j.bbmt.2015.03.018
61. Gøtzsche P.C., Johansen H.K. Routine versus selective antifungal administration for control of fungal infections in patients with cancer. Cochrane Database Syst Rev. 2014;(9)CD000026. DOI: 10.1002/14651858.CD000026.pub2
62. Robenshtok E., Gafter-Gvili A., Goldberg E., et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: Systematic review and meta-analysis. J Clin Oncol. 2007;25:5471-5489. DOI: 10.1200/JCO.2007.12.3851
63. Del Castillo M., Romero F.A., Arguello E., et al. The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma. Clin Infect Dis. 2016;63:1490-1493. DOI: 10.1093/cid/ciw539
64. US Food and Drug Administration: Aliqopa (copanlisib): Highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209936s000lbl.pdf.
65. Gilead Sciences: Zydelig: Highlights of prescribing information. http://www.gilead.com/~/media/CF1E73FFB80B42E2A39F9F5758DB3001.ashx.
66. Huang H., Li X., Zhu J., et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: A randomized clinical trial. JAMA. 2014;312:2521-2530. DOI: 10.1001/jama.2014.15704
67. Mozessohn L., Chan K.K., Feld J.J., et al. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: A meta-analysis. J Viral Hepat. 2015;22:842-849. DOI: 10.1111/jvh.12402
68. US Centers for Disease Control and Prevention: Advisory committee on immunization practices. https://www.cdc.gov/vaccines/acip/index.html.
69. Kim D.K., Riley L.E., Hunter P. Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older: United States, 2018. MMWR Morb Mortal Wkly Rep. 2018;67:158-160. DOI: 10.15585/mmwr.mm6705e3
70. Mikulska M., Cesaro S., de Lavallade H., et al. Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019 Feb 7. pii: S14733099(18)30601-7. DOI: 10.1016/S1473-3099(18)30601-7
71. Cordonnier C., Einarsdottir S., Cesaro S., et al. Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019 Feb 7. pii: S1473-3099(18)30600-5. DOI: 10.1016/S1473-3099(18)30600-5
72. Boyce J.M., Pittet D. Guideline for hand hygiene in health-care settings: Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force – Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America. MMWR Recomm Rep. 2002;51:1-45.
73. Sonbol M.B., Firwana B., Diab M., et al. The effect of a neutropenic diet on infection and mortality rates in cancer patients: A meta-analysis. Nutr Cancer. 2015;67:1230-1238. DOI: 10.1080/01635581.2015.1082109
74. Sullivan K.M., Dykewicz C.A., Longworth D.L., et al. Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. Hematology Am Soc Hematol Educ Program. 2001:392-421. DOI: 10.1182/asheducation-2001.1.392
75. Zimmer A.J., Freifeld A.G. Optimal management of neutropenic fever in patients with cancer. J Oncol Pract. 2019;15:19-24. DOI: 10.1200/JOP.18.00269
76. Rhodes A., Evans L.E., Alhazzani W., et al. Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock – 2016. Crit Care Med. 2017;45:486-552. DOI: 10.1007/s00134-017-4683-6
77. IDSA Sepsis Task Force: IDSA position statement: Why IDSA did not endorse the Surviving Sepsis Campaign guidelines. Clin Infect Dis. 2018;66:1631-1635. DOI: 10.1093/cid/cix997

Views

0 Abstract

0 PDF

0 Crossref citations

Review of the ASCO and IDSA clinical practice guidelines on antimicrobial prophylaxis for adult patients with cancer-related immunosupression

Abstract

Views

Shared

Cited by Crossref